Less than a year after garnering the first anti-CLDN18.2 approval in the U.S., Astellas Pharma is not resting on its laurels.

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Instead, Stealth submitted a new drug application (NDA) seeking approval of elamipretide and the FDA issued its ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

A Dutch neuromodulation developer has raised $60 million to complete the development of its minimally invasive implant for ...